Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC).

Lung cancer (Amsterdam, Netherlands) - 1 Mar 2026

Barsouk Adam, Heidlauf Alec, Goel Keshav, Rushkin Lynn, Anran Huang Anna, Elghawy Omar, Yu Connie, Wang Lucy, Yang David, Kurian Martin, Reed-Guy Lauren, Sun Lova, Singh Aditi, Aggarwal Charu, Cohen Roger B, Langer Corey, Marmarelis Melina E

Abstract excerpt

INTRODUCTION: Osimertinib has become standard of carein 1 LEGFR-mutated(mt)mNSCLC following the FLAURA trial.However, limited data are available on the effect of osimertinib dose-reductionon outcomes compared tofull-dose. METHODS: We performed a single-institution, retrospective analysis of pts withEGFR-mt mNSCLC treated with 1 L osimertinib from 2018 to 2023. Pts who underwent dose-reduction were compared to...

Topics

Join the communities discussing this publication.

Acrylamides
Aniline Compounds
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 41570773
DOI: 10.1016/j.lungcan.2026.108936

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC).PMID 41570773Read ↗

Association Between Osimertinib Dose Reduction and Treatment Outcomes in First-Line EGFR-Mutated Advanced NSCLC: The Impact of Post-Progression Management.Semantic proximity Read ↗

Clinical Impact of Osimertinib Dose Reduction in the First-Line Setting on EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Monocentric StudySemantic proximity Read ↗

Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Early dose reduction of osimertinib in advanced EGFR -mutated non-small cell lung cancer.Semantic proximity Read ↗

Osimertinib early dose reduction as a risk to brain metastasis control in EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Reduced frequency dosing of osimertinib in EGFR-mutant non-small cell lung carcinoma: Real world dataSemantic proximity Read ↗

EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.Semantic proximity Read ↗

Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib.Semantic proximity Read ↗

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.Semantic proximity Read ↗

Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment.Semantic proximity Read ↗

Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.